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Abstract 
Background: Impaired vasoreactivity is often observed in subjects with metabolic syndrome, a condition that 
includes the presence of a specific cluster of risk factors for obesity and cardiovascular disease. However, hierarchi-
cal causes in the impaired vasoreactivity have not been clarified. We evaluated the impact of individual metabolic 
risk components or its clustering under the condition of insulin resistance on endothelial and smooth muscle cell 
function.
Methods: Vascular reactivity to acetylcholine (Ach), with or without nitric oxide synthase (NOS) inhibitor NG-mon-
omethyl-l-arginine (L-NMMA), or sodium nitroprusside (SNP) by forearm venous occlusion plethysmography and 
insulin sensitivity index (M mg/kg/min) in euglycemic clamp were measured in men without (n = 18, control group) 
or with (n = 19, metabolic syndrome group) metabolic syndrome.
Results: (1) Ach-induced maximal forearm blood flow (maxFBF) was impaired in subjects with metabolic syndrome. 
In particular, the NOS-dependent component of Ach-induced maxFBF was selectively decreased, while the NOS-
independent component remained relatively unchanged. (2) Ach-induced maxFBF and ∆Ach-induced maxFBF with 
L-NMMA were correlated with waist circumference, glucose, and triglycerides, and most strongly correlated with vis-
ceral fat area, adiponectin, and M. (3) Multivariate regression analysis indicated that individual metabolic risk compo-
nents explained Ach-induced maxFBF by 4–21 %. Clustering of all metabolic risk components increased this to 35 %, 
and the presence of metabolic syndrome explained 30 %, indicating that defining metabolic syndrome can effectively 
predict impairment of endothelial dysfunction.
Conclusions: Endothelial dysfunction was correlated with individual metabolic risk components, but more strongly 
with clustering of the components under a condition with low insulin sensitivity. We suggest that in subjects with 
metabolic syndrome, endothelial function is impaired by multiple cardiovascular risk factors exclusively when under 
the condition of insulin insensitivity and also that defining metabolic syndrome can effectively predict impairment of 
endothelial dysfunction.
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Background
Metabolic syndrome is a condition that includes the pres-
ence of a specific cluster of risk factors for obesity and 
cardiovascular disease, including abdominal obesity, high 
blood pressure, impaired fasting blood glucose, hypertri-
glyceridemia and low HDL cholesterol [1]. Of note, the 
clinical utility of metabolic syndrome has been ques-
tioned [2, 3], because different definitions and different 
clusterings of components of metabolic syndrome may 
result in variations in cardiovascular risk predictions [4].
Impairment of vasoreactivity has been observed in 
patients with traditional coronary risk factors, even in 
the absence of morphological atherosclerotic lesions [5]. 
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Accordingly, the assessment of vasoreactivity can provide 
pivotal information as a diagnostic and prognostic tool in 
patients at risk for atherosclerotic cardiovascular disease 
[6, 7]. The vasoreactivity is often impaired in subjects 
with metabolic syndrome [8, 9]. Hence, the impaired vas-
oreactivity in this syndrome can be provoked by two sce-
narios [1]: (1) individual metabolic risk components such 
as high blood pressure, hyperglycemia, and dyslipidemia, 
or (2) its clustering under the condition of obesity and/
or insulin resistance. However, the principal scenario for 
the vascular dysfunction in metabolic syndrome remains 
obscure.
The current study compared the impact of individ-
ual metabolic risk components and its clustering under 
the condition of obesity and/or insulin resistance on 




Male subjects were divided into either the group with-
out metabolic syndrome (n  =  18, control group) or 
with metabolic syndrome (n  =  19, MS group). A sub-
ject was defined as having metabolic syndrome as per 
the guidelines outlined in the IDF consensus statement 
[10]. Therefore, the subject had metabolic syndrome if 
he was obese (according to the Japanese criteria, hav-
ing a waist circumference  ≥85  cm in men) and had 
any two of the following four factors: (1) hypertriglyc-
eridemia [serum triglyceride concentration  ≥150  mg/
dL (1.69  mmol/L)], (2) a low HDL cholesterol level 
[serum HDL cholesterol concentration of 40  mg/dL 
(1.04  mmol/L)], (3) an elevated blood pressure (sys-
tolic blood pressure  ≥130  mmHg and/or diastolic 
blood pressure  ≥85  mmHg) or was taking anti-hyper-
tensive drugs, and (4) a high fasting plasma glucose 
level [fasting plasma glucose concentration  ≥100  mg/
dL (5.6 mmol/L)]. Participants who were taking insulin 
regimen or oral anti-diabetic drugs were excluded. Waist 
circumference was measured in the standing position 
and subcutaneous fat area (SFA) and intra-abdominal 
visceral fat area (VFA) were determined at the level of 
the umbilicus using a standardized method involving 
computed tomography [11]. Subjects were instructed to 
refrain from vigorous exercise, anti-hypertensive drugs, 
anti-hyperlipidemic drugs, non-steroidal anti-inflamma-
tory drugs, alcohol, smoking and caffeine for 24 h prior 
to the study day. The study protocol was approved by the 
Ethical Committee of the University of the Ryukyus, and 
obeyed to the standards set by the Declaration of Hel-
sinki. Written informed consent was obtained from all 
subjects.
Biochemical measurements
Venous blood samples were obtained in tubes contain-
ing EDTA-sodium (1  mg/mL) and in polystyrene tubes 
without an anticoagulant. The EDTA-containing tubes 
were promptly chilled. Plasma was immediately separated 
by centrifugation at 3000  rpm and 4  °C for 10  min, and 
serum isolated by centrifugation at 1000  rpm at room 
temperature for 10  min. Samples were stored at −80  °C 
until they were assayed. Routine chemical methods were 
used to determine the serum concentrations of total cho-
lesterol, HDL cholesterol, triglycerides, creatinine, glu-
cose, and electrolytes. The serum concentration of LDL 
cholesterol was estimated using Friedewald’s method [12].
Euglycemic hyperinsulinemic clamp
The whole-body insulin sensitivity index (M) was measured 
using a hyperinsulinemic euglycemic clamp [13] with mod-
ifications [14] for 180 min. A primed continuous infusion 
of insulin (10.8  pmol  kg−1  min−1, Novo-Nordisk, Japan) 
was administered along with a variable rate infusion of 20 % 
dextrose (Baxter Health Care, Japan) that was adjusted 
manually to maintain serum glucose of 5.2  mmol/L. This 
was determined based on arterialized samples withdrawn 
every 5  min from an ipsilateral right dorsal hand vein 
(heated-air blanket was kept at 55  °C). The M value (mg/
kg/min) was calculated during the last 30 min of the study.
Vascular reactivity
Forearm blood flow (FBF) was measured simultaneously in 
both forearms by bilateral venous occlusion plethysmogra-
phy with mercury-in-silicone elastomer strain gauges, as 
described [14]. All subjects were supine in a quiet, air-con-
ditioned room, with both forearms resting slightly above 
their heart level. Acetylcholine (Ach, 0–400  nmol/min) 
with or without NG-monomethyl-l-arginine (L-NMMA, 
8  µmol/min), a nitric oxide synthase (NOS) inhibitor, or 
sodium nitroprusside (SNP, 0–30 nmol/min) was infused 
into a 27-gauge catheter inserted into the brachial artery 
of the non-dominant arm by volumetric precision pumps. 
The infusion rate was maintained at 1  mL/min through-
out the study unless otherwise indicated. All FBF data 
were obtained via a Mac Lab Version 4 chart recorder (AD 
Instruments, Hamstead, London, United Kingdom).
Statistical analysis
Values are expressed as the mean ± SD. Comparisons of 
vascular responses were analyzed by two-way analysis of 
variance (ANOVA) for repeated measures on one fac-
tor, followed by Holm–Sidak multiple comparison test 
to compare group means. Simple regression analysis was 
used to identify significant linear associations of vascular 
responses with components of the metabolic syndrome 
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and related variables. Multiple regression analysis for 
vascular reactivity was performed in standard sequential 
(hierarchical) models and in a stepwise backward model 
using variables of individual components in the definition 
of metabolic syndrome and markers for possible underly-
ing mechanisms. All analyses were performed using Jump 
version 12.1.0 software (SAS Institute Inc., Cary, NC). A 
P value of <0.05 was considered statistically significant.
Results
General characteristics
Subject characteristics are summarized in Table  1. All 
subjects with or without metabolic syndrome completed 
the study. Subjects in the MS group were clinically obese, 
and displayed a higher body weight, BMI, and waist cir-
cumference than subjects without metabolic syndrome. 
The MS group also had greater SFA and VFA. There were 
no significant differences in age, heart rate, or smoking 
status (control 20 %, MS 16 %) between the two groups. 
The MS group exhibited higher levels of fasting glucose, 
insulin, HbA1c, total and LDL cholesterol, and triglycer-
ides and lower levels of HDL cholesterol than the control 
group. The MS group exhibited lower adiponectin than 
the control group (p < 0.0001). In addition, M values were 
reduced by half in the MS group.
Vascular reactivity
Vascular responsiveness to Ach
Basal FBF was 3.4 ± 1.3 mL/min/100 mL in the control 
group and 3.2 ±  1.2  mL/min/100  mL in the MS group 
(p = 0.663). As shown in Fig. 1a, Ach-induced maximal 
FBF (Ach-induced maxFBF) (•) was reduced in the MS 
group (14.0 ± 4.5 mL/min/100 mL) compared to the con-
trol group (24.2 ± 8.0 mL/min/100 mL, p < 0.0001).
NOS‑dependent vasodilation
Ach-induced maximal FBF during co-infusion of 
L-NMMA was reduced to 14.3 ± 5.2 mL/min/100 mL in 
the control group, but was not reduced in the MS group 
(13.0  ±  4.8  mL/min/100  mL) (Fig.  1a). The decline in 
Ach-induced maximal FBF by L-NMMA (∆maxFBF by 
L-NMMA), which represents the NOS-dependent vaso-
dilation, was 10.2 ± 6.7 and 2.1 ± 2.4 mL/min/100 mL, 
respectively (p < 0.0001).
Smooth muscle responsiveness to SNP
As shown in Fig. 1b, SNP-induced maximal FBF (SNP-
induced maxFBF) was also reduced in the MS group 
compared to control group: the SNP-induced maxFBF 
was 19.5  ±  8.0  mL/min/100  mL in the control group 
and 14.4  ±  5.0  mL/min/100  mL in the MS group 
(p = 0.021).
Vascular reactivity and components of metabolic 
syndrome
To explore the contributions of individual metabolic risk 
components to altered vascular control, the relationships 
between the components and endothelial and vascular 
smooth muscle responses were assessed. Significant rela-
tionships were observed between Ach-induced maxFBF 
and waist circumference, glucose, and triglycerides, such 
that higher levels of these components were associated 
with lower vasodilation (Fig.  2). SNP-induced maxFBF 
was correlated only with glucose. In addition, ∆maxFBF 
by L-NMMA was correlated with SBP, glucose and 
triglycerides.
Vascular reactivity, abdominal fat distribution, 
adiponectin, and insulin sensitivity
Next, we evaluated the impact of VFA, SFA, adiponec-
tin, and M value, the  markers for possible underly-
ing mechanisms, on Ach-induced maxFBF (Fig.  3). A 
strong negative relationship was observed between Ach-
induced maxFBF and VFA, but not SFA. Ach-induced 
maxFBF was positively correlated with adiponectin, and 
most strongly correlated with M value. SNP-induced 
maximal FBF was not correlated with VFA, SFA, or adi-
ponectin, but was positively correlated with M value. The 
∆maxFBF by L-NMMA was correlated with SBP, glucose 
and triglycerides. In addition to Ach-induced maxFBF, 
∆maxFBF by L-NMMA was negatively correlated with 
VFA, and positively correlated with adiponectin and M 
value.
Table 1 General characteristics of the studied patients





Age (years) 48 ± 15 51 ± 9
Body weight (kg) 65.3 ± 8.4 76.4 ± 8.3**
Body mass index (kg/m2) 23.1 ± 2.3 27.8 ± 2.7**
Waist circumference (cm) 84.1 ± 9.8 93.9 ± 7.2**
Systolic blood pressure 
(mm Hg)
121 ± 13 134 ± 19**
Diastolic blood pressure 
(mm Hg)
74 ± 7 81 ± 10*
Heart rate (beats/min) 68 ± 8 68 ± 11
Glucose (mmol/L) 5.7 ± 1.6 7.5 ± 2.7*
Insulin (pmol/L) 44.5 ± 28.9 79.0 ± 42.0**
Haemoglobin A1c (%) 5.4 ± 1.1 7.0 ± 2.1*
LDL cholesterol (mmol/L) 2.79 ± 0.70 3.13 ± 0.66
HDL cholesterol (mmol/L) 1.41 ± 0.48 1.22 ± 0.20
Triglyceride (mmol/L) 1.12 ± 0.70 2.53 ± 1.04**
Adiponectin (log µg/ml) 0.87 ± 0.15 0.72 ± 0.12**
M (mg/kg/min) 7.81 ± 2.86 4.14 ± 2.04**
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Multivariate regression analysis of vascular reactivity 
determinants
Next, we determined the impact of individual meta-
bolic risk components or the clustering of components 
on vascular reactivity by multivariate regression models 
(Table 2).
For Ach-induced maxFBF, waist circumference 
(model 1) and triglycerides, but not blood pressure, glu-
cose or HDL cholesterol (data not shown), were deter-
minants of vascular reactivity, even after correcting for 
age and smoking status. Clustering of 5 components 
increased the corrected R2 (model 2), and addition 
of M value to the clustering of 5 components further 
increased the corrected R2, which reached 0.514 (model 
3). Meanwhile, the presence of metabolic syndrome, 
though slightly decreased compared to the clustering of 
5 components, was also a determinant of Ach-induced 
maxFBF (model 4); addition of M value to the pres-
ence of metabolic syndrome increased the corrected R2 
(model 5).
For SNP FBF, waist circumference (model 1), blood 
pressure, plasma glucose, triglycerides, and HDL choles-
terol (data not shown), were not determinants of vascular 
reactivity. Clustering of these components with or with-
out M value (models 2 and 3), and the presence of meta-
bolic syndrome with or without M value (models 4 and 5) 
were also not determinants of vascular reactivity.
For ∆maxFBF by L-NMMA, waist circumference 
(model 1) and triglycerides, but not blood pressure, glu-
cose or HDL cholesterol (data not shown), were determi-
nants of vascular reactivity. Clustering of 5 components 
and the presence of metabolic syndrome increased the 
corrected R2 value (models 2 and 3), and addition of M 
value further increased the corrected R2 value (models 4 
and 5).
In the stepwise backward model (model 6) including 
the above individual components, defining metabolic 
syndrome and M value were significant predictors of 
Ach-induced maxFBF, M value for SNP-induced maxFBF, 
and defining metabolic syndrome for ∆maxFBF by 
L-NMMA.
Vascular reactivity and the number of components 
of metabolic syndrome
Finally, we evaluated the relationship between vascu-
lar reactivity and the number of metabolic risk compo-
nents in subjects with or without visceral obesity (Fig. 4). 
In subjects without visceral obesity (waist circumfer-
ence  <85  cm), subjects with 1 or  ≥2 of 4 components, 
which included a high level of fasting glucose, elevated 
blood pressure, hypertriglyceridemia, and a low level of 
HDL cholesterol, did not show a statistical difference in 
Ach-induced maxFBF, SNP and ∆maxFBF by L-NMMA, 
compared to the group with 0 component. There were 
no significant differences in VFA, adiponectin and M 
value among the subgroups with 0, 1 and  ≥2 compo-
nents. In subjects with visceral obesity (waist circumfer-
ence ≥85 cm), Ach-induced maxFBF was not decreased 
in the group with 1 component compared to the group 
with 0 component, but was decreased in the group 
with ≥2 components. SNP was not different among the 
subgroups with 0, 1 and ≥2 components. The ∆maxFBF 
by L-NMMA was decreased in accordance with the num-
ber of the components. In the group with  ≥3 compo-
nents, there were no significant differences in VFA and 
adiponectin, but M value was significantly decreased.
Fig. 1 Forearm vascular reactivity to a ACh, with or without the nitric oxide synthase (NOS) inhibitor L-NMMA (8 μmol/min), or b SNP, as measured 
by bilateral venous occlusion plethysmography in subjects without (n = 18) or with (n = 19) metabolic syndrome. FBF was measured simultane-
ously in subjects infused with Ach (closed circles), SNP (closed circles) or Ach plus L-NMMA (gray circles) and non-infused arms (open circles) using 
bilateral venous occlusion plethysmography. FBF forearm blood flow, ACh acetylcholine, L-NMMA NG-monomethyl-l-arginine, SNP sodium nitroprus-
side. Data are expressed as mean ± SD
Page 5 of 11Shimabukuro et al. Cardiovasc Diabetol  (2016) 15:77 
Discussion
The new findings of this study are: (1) Ach-induced 
and SNP-induced maximal FBFs were impaired in sub-
jects with metabolic syndrome. In particular, we first 
found that the NOS-dependent component of Ach-
induced maxFBF was selectively decreased, while the 
NOS-independent component remained unchanged. 
(2) Ach-induced maximal FBF and ∆Ach-induced 
maximal FBF by L-NMMA, and SNP-induced maxi-
mal FBF were correlated strongly with M value than 
with individual metabolic components. (3) Multivari-
ate regression models clearly indicated that defining 
metabolic syndrome, as compared to individual meta-
bolic components, predicts impairment of endothelial 
dysfunction.
Vascular reactivity
As observed in previous studies of obese subjects [15, 
16], Ach-induced maxFBF, a marker of endothelial func-
tion, was reduced in MS group. We further investigated 
vascular NO bioavailability by comparing the dose–
response curves of Ach with and without pharmaco-
logical NOS inhibition. In the NO clamp technique, the 
NOS-dependent and NOS-independent components 
of FBF can be accurately determined [17]. Co-infusion 
of L-NMMA and Ach caused a decrease in the level of 
inhibition of Ach-induced maxFBF in subjects with 
metabolic syndrome, and equalized the Ach-induced 
maximum FBF during NOS inhibition between the two 
groups. This implies that the NOS-dependent compo-
nent of Ach-induced maxFBF was selectively decreased 
in subjects with metabolic syndrome, while the NOS-
independent component remained relatively unchanged.
Classically, it has been believed that endothelial func-
tion is impaired, even in the first step of atherosclerosis, 
but smooth muscle cell function is preserved even in the 
advanced stages of atherosclerosis [5]. Conversely, cur-
rent study showed that SNP-induced maximal FBF, a 
marker of smooth muscle responsiveness, was reduced 
in the MS group. The data obtained during NO inhibi-
tion by L-NMMA, suggest that the whole difference in 
Ach reactivity between two groups can be mainly due 
to a defect in the NOS-dependent NO synthesis. How-
ever, the impaired smooth muscle vasorelaxation sug-
gests an impaired bioavailability and/or responsiveness 
to endogenous NO [18]. Given that the response to Ach 
was superimposable at the levels in NO synthesis and/
or its biological activities, the contradictory findings may 
Fig. 2 Simple regression analysis between vascular reactivity and components of metabolic syndrome in men without (n = 18, open circles) or 
with (n = 19, gray circles) metabolic syndrome. FBF at an Ach infusion of 400 nmol/min, FBF at an SNP infusion of 30 nmol/min, and ∆Ach-induced 
maximal FBF by co-infusion of L-NMMA at 8 μmol/min. Linear regression analysis was done, and r and p values are shown
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be partially explained by a converse compensation for 
the loss in NO bioavailability [18]. Endothelium-derived 
hyperpolarizing factor (EDHF) pathway, in which altera-
tions was reported under pathological conditions, might 
be one such candidate [19]. Fernandes et  al. reported 
that time-to-peak after hyperemia rather than flow 
mediated dilation (FMD) distinguished metabolic syn-
drome from healthy controls [20]. In the time-course 
analysis of FMD [21], time to peak after hyperemia is 
not influenced by L-NMMA inhibition, suggesting that 
other factors, such as differences in vascular compliance 
and transduction independently of the NOS pathway 
[20, 22].
Vascular reactivity, abdominal fat distribution, adiponectin 
and insulin sensitivity
In the current study, Ach-induced maximal FBF, 
and ∆Ach-induced maximal FBF by L-NMMA were 
correlated with waist circumference, glucose and tri-
glycerides, and more strongly with M value. This result 
agrees with a previous study [15] where Steinberg 
et  al. report that obesity/insulin resistance is associ-
ated with both blunted endothelium-dependent vaso-
dilation and failure of euglycemic hyperinsulinemia to 
augment endothelium-dependent vasodilation. This 
suggests that obese/insulin-resistant subjects are char-
acterized by endothelial dysfunction and endothe-
lial resistance to insulin’s effect on enhancement of 
endothelium-dependent vasodilation. Our results fur-
ther indicated that each of abdominal fat distribution, 
adiponectin, and insulin sensitivity was correlated with 
Ach-induced maximal FBF and ∆Ach-induced maxi-
mal FBF by L-NMMA more greatly than each of the 
MS components. Therefore, endothelial function in 
metabolic syndrome can be explained mostly by mutu-
ally dependent insulin resistance, visceral obesity and 
Fig. 3 Simple regression analysis between vascular reactivity, abdominal fat distribution, adiponectin and insulin sensitivity index (M) in men 
without (n = 18, open circles) or with (n = 19, gray circles) metabolic syndrome. FBF at an Ach infusion of 400 nmol/min, FBF at an SNP infusion of 
30 nmol/min, and ∆Ach-induced maximal FBF by co-infusion of L-NMMA at 8 μmol/min. Pearson’s correlation coefficients and p values are shown
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hypoadiponectinemia through increased production of 
reactive oxidative species (ROS) and proinflammatory 
cytokines [11, 23–29].
Impairment in the SNP-induced maximal FBF was 
also correlated with M value as well as in Ach-induced 
maximal FBF. The observation may be supported by 
Schinzari et al. showing that the vascular responsiveness 
to both Ach and SNP was not enhanced during hyperin-
sulinemia in patients with metabolic syndrome [30]. They 
suggests that insulin’s facilitator action on the vasodilator 
Table 2 Multivariate regression analysis fo vascular reactivity
a Model 1–5: standard multiple regression analysis
b Model 6: stepwise multiple regression analysis
Model 1a Model 2a Model 3a Model 4a Model 5a Model 6b
Ach-induced maximal forearm blood flow (FBF)
Corrected R2 0.228 0.347 0.514 0.297 0.429 0.522
P value 0.009 0.006 0.001 0.002 0.000 0.000
Variables E P E P E P E P E P E P
Age (years) −0.153 0.156 −0.018 0.868 0.085 0.427 −0.109 0.288 0.016 0.883 0 0.712
Current smoking (yes or no) 1.246 0.336 0.532 0.665 −0.770 0.517 0.188 0.876 −0.991 0.419 0 0.562
Waist circumference (cm) ≥85 cm (yes or no) 4.749 0.002 3.387 0.024 2.137 0.116 0 0.134
SBP ≥130 or DBP ≥85 mmHg or use of antihyper-
tensive drugs
1.931 0.146 2.613 0.046 0 0.326
Glucose ≥100 mg/dL (yes or no) 1.947 0.131 −0.374 0.771 0 0.184
Triglycerides ≥150 mg/dL (yes or no) 2.230 0.095 1.305 0.298 0 0.490
HDL-cholesterol ≥150 mg/dL (yes or no) 1.065 0.456 1.493 0.286 0 0.965
Metabolic syndrome (yes or no) 4.675 0.000 −3.120 0.022 −3.560 0.006
M (mg/kg/min) 1.424 0.005 1.258 0.012 1.186 0.005
SNP-induced maximal forearm blood flow (FBF)
Corrected R2 0.123 0.117 0.148 0.173 0.224 0.254
P value 0.063 0.159 0.152 0.026 0.022 0.0017
Variables E P E P E P E P E P
Age (years) −0.233 0.020 −0.153 0.168 −0.114 0.346 −0.213 0.029 −0.151 0.162 0 0.240
Current smoking (yes or no) 1.239 0.293 0.875 0.474 0.229 0.864 0.848 0.448 0.232 0.848 0 0.906
Waist circumference (cm) ≥85 cm (yes or no) 1.669 0.202 1.477 0.304 0.507 0.735 0 0.818
SBP ≥130 or DBP ≥85 mmHg or use of antihyper-
tensive drugs
0.437 0.736 1.123 0.432 0 0.415
Glucose ≥100 mg/dL (yes or no) 2.355 0.069 0.649 0.655 0 0.438
Triglycerides ≥150 mg/dL (yes or no) −0.091 0.944 −0.810 0.563 0 0.726
HDL-cholesterol ≥150 mg/dL (yes or no) 0.792 0.576 1.492 0.343 0 0.519
Metabolic syndrome (yes or no) −2.120 0.061 −1.022 0.430 0 0.336
M (mg/kg/min) 0.872 0.107 0.784 0.103 1.237 0.002
∆Ach-induced maximal forearm blood flow (FBF) by L-NMMA
Corrected R2 0.236 0.460 0.594 0.406 0.533 0.481
P value 0.009 0.001 0.000 0.000 <0.0001 <0.0001
Variables E P E P E P E P E P E P
Age (years) −0.179 0.029 −0.071 0.344 −0.013 0.866 −0.145 0.045 0.074 0.415 0 0.094
Current smoking (yes or no) 0.635 0.512 −0.007 0.993 −0.726 0.397 −0.069 0.935 0.854 0.407 0 0.558
Waist circumference (cm) ≥85 cm (yes or no) 3.048 0.008 1.975 0.068 1.112 0.265 0 0.918
SBP ≥130 or DBP ≥85 mmHg or use of antihyper-
tensive drugs
1.874 0.049 2.161 0.028 0 0.216
Glucose ≥100 mg/dL (yes or no) 1.541 0.085 0.141 0.877 0 0.594
Triglycerides ≥150 mg/dL (yes or no) 1.731 0.073 1.403 0.131 0 0.360
HDL-cholesterol ≥150 mg/dL (yes or no) 1.673 0.100 1.856 0.075 0 0.774
Metabolic syndrome (yes or no) −3.627 0.000 0.950 0.008 −15.01 0.000
M (mg/kg/min) 0.867 0.015 0.341 0.021 0 0.112
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machinery was caused by endothelium unresponsiveness 
(a decrease in NO synthesis and/or a loss of its biologi-
cal activities) and by defective sensitization of smooth 
muscle vasorelaxation (a loss in NO bioavailability) [19]. 
Aoqui et al. found distinct patterns of microvascular dys-
function in metabolic syndrome, with augmented vaso-
constriction present in the initial phase of metabolic 
syndrome independent of endothelial dysfunction [31]. 
Reportedly, locally produced ROS [25] and/or fat-derived 
ROS [23] can react with NO, generate peroxynitrite, and 
impair cyclic GMP-dependent vasodilatation; this mech-
anism may partially explain these smooth muscle cell 
dysfunction [18, 31].
Impact of individual metabolic risk components and its 
clustering on endothelial and smooth muscle cell function
Since metabolic syndrome is a cluster of relatively het-
erogeneous atherosclerotic risk factors, which may solely 
impair endothelial function, we evaluated the relation-
ship between vascular reactivity and individual com-
ponents or its clustering. In a simple regression model 
(Fig.  2), the Ach-induced maxFBF and ∆maxFBF by 
L-NMMA were lineally correlated with waist circumfer-
ence, glucose and triglycerides. However, multivariate 
regression analysis indicated that individual components 
explained only partially Ach-induced maxFBF by 4–21 %, 
∆maxFBF by L-NMMA by 6–31  %, and SNP-induced 
maxFBF by 8–17 % (data not shown). In model 3, includ-
ing the 5 components of visceral obesity, high fasting glu-
cose, elevated blood pressure, hypertriglyceridemia, and 
a low level of HDL cholesterol, increased the assumption 
to 35 % in Ach-induced maxFBF and 46 % in ∆maxFBF by 
L-NMMA, but only 16 % in SNP-induced maxFBF. These 
results support the notion that clustering of the compo-
nents more greatly estimates endothelial dysfunction 
than individual components, but not smooth muscle cell 
function. Notably, the presence of metabolic syndrome, 
while still slightly less than the clustering of 5 compo-
nents (model 2), explained 30 % of Ach-induced maxFBF 
and 41  % of ∆maxFBF by L-NMMA (model 4). These 
findings support the notion that defining metabolic syn-
drome is effective in predicting endothelial dysfunction, 
which can subsequently predict future cardiovascular 
events [5, 7]. In the current study, type 2 diabetes mel-
litus was prevalent in the MS group (12/18, 67  %) than 
in the control group (4/19, 21  %) (p  <  0.05). When all 
patients divided into diabetic and non-diabetic groups, 
Ach-induced maxFBF (21.5  ±  1.7 vs 16.0  ±  2.0  mL/
min/100  mL, p  =  0.040), ∆maxFBF by L-NMMA 
(8.3 ± 6.8 vs 2.8 ± 4.2 mL/min/100 mL, p = 0.008) and 
Fig. 4 The relationship between vascular reactivity and number of components of metabolic syndrome in men without visceral obesity (n = 12, 
waist circumference <85 cm) or with visceral obesity (n = 25, waist circumference ≥85 cm). Subjects were divided into groups with 0, 1 or 2 ≥of 
the following metabolic syndrome components: high level of fasting glucose, elevated blood pressure, hypertriglyceridemia, and low level of HDL 
cholesterol. Data are expressed as mean ± SD. Statistical analysis was done by two-way analysis of variance (ANOVA), followed by Holm–Sidak 
multiple comparison test to compare group means. P values = * <0.05, *** <0.001 vs. the 0 group
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SNP-induced maxFBF (19.4  ±  1.4 vs 13.6  ±  1.7  mL/
min/100  mL, p  =  0.011) were all impaired in diabetic 
groups. Vascular function in type 2 diabetes mellitus is 
also confounded by cardiovascular risk factors, such as 
obesity, hypertension and dyslipidemia, suggesting sig-
nificance of cardiovascular risk clustering [32].
In our study, endothelial function is not strongly cor-
related with individual metabolic risk components, 
but strongly with insulin resistance. Thus, it is assumed 
that recovery of vascular function can be obtained less 
effectively by improvement of individual metabolic 
parameters [33], but more effectively by improvement 
of metabolic syndrome or insulin resistance [34]. This 
notion may be supported by the fact in patients with 
metabolically healthy obesity (MHO), a medical condi-
tion characterized by obesity which does not produce 
metabolic complications such as dyslipidemia, impaired 
glucose tolerance or hypertension [35]. The MHO had 
abnormal vascular reactivity, although their endothelial 
dysfunction was less pronounced than in patients with 
metabolic syndrome, indicating that obesity is associated 
with vascular damage independent of those metabolic 
abnormalities underlying metabolic syndrome [36].
We also evaluated the relationship between vascular 
reactivity and the number of metabolic syndrome com-
ponents (Fig.  4). In subjects without visceral obesity, 
there were no differences in Ach-induced maxFBF and 
∆maxFBF by L-NMMA among patients with 0, 1 and 
2≥  of the 4 selected components. In contrast, in sub-
jects with visceral obesity, Ach-induced maxFBF and 
∆maxFBF by L-NMMA decreased in subjects with  ≥2 
components. As such, one or two components cannot 
be sufficient to cause impairment of endothelial function 
even in subjects with visceral obesity, but the clustering 
of  ≥2 components can be sufficient. Interestingly, sub-
jects without visceral obesity that have ≥2 components 
showed a subtler endothelial dysfunction than subjects 
with visceral obesity. This notion agrees with the previous 
study of Li et al., where they showed impaired endothelial 
function in subjects with metabolic syndrome as com-
pared to individuals with a similar burden of traditional 
cardiovascular risk factors, but without metabolic syn-
drome [37]. Their multivariate regression model found 
that after adjustment for covariates and 6 traditional car-
diovascular risk factors, the presence of metabolic syn-
drome had a significant and independent influence on 
endothelial function (p < 0.01).
In our multivariate model, addition of M value 
increased the corrected R2 for Ach-induced maxFBF to 
51 % in the model including all the components (model 
3) and to 43  % in the model including the presence of 
metabolic syndrome (model 5). Insulin resistance should 
play a pivotal role in causing endothelial dysfunction by 
comorbidity of the metabolic syndrome components. 
We also found that endothelial function, indicated by 
Ach-induced maxFBF and ∆maxFBF by L-NMMA, was 
impaired in the group with ≥2 components, and M value 
decreased according to the number of components. Col-
lectively, our data suggest that in subjects with visceral fat 
obesity, endothelial function is impaired by multiple car-
diovascular risk factors exclusively when under the con-
dition of insulin insensitivity.
Study limitations
First, we obtained data from a small number of sub-
jects; therefore, there was the risk of type II errors. 
The strain gauge plethysmography and the euglycemic 
hyperinsulinemic clamp techniques, used in the study 
for measurement of vascular function and insulin sen-
sitivity, are sensitive and solid, but the time-consuming 
and invasive characteristics limits number of partici-
pants. In contrast, alternative simplified methods such 
as flow-mediated dilation (FMD) [38] and HOMA-IR 
[39] are good for recruiting participants, but the reli-
ability is limited. Thus, current results should be con-
firmed by combinations of multiple techniques and 
clinical studies with different size. Second, this cross-
sectional study has shown only a correlation between 
vascular dysfunction and insulin resistance in subjects 
with metabolic syndrome, and has not indicated a 
cause-effect relationship. In future studies, we need to 
confirm that a therapeutic approach to improve insulin 
sensitivity by such as reductions in visceral fat obesity 
and ectopic fat deposition can recover vascular dys-
function in metabolic syndrome. Third, since metabolic 
syndrome is a cluster of relatively heterogeneous ath-
erosclerotic risk factors, which solely affect endothe-
lial function, careful consideration should be taken to 
evaluate underlying mechanisms. Forth, we could not 
determine the molecular mechanisms by which insu-
lin resistance occurs and impairs endothelial function 
from the current study.
Conclusions
The current study evaluated the impact of individual 
metabolic risk components or its clustering on endothe-
lial and smooth muscle cell function in subjects with 
metabolic syndrome. The endothelial and smooth muscle 
cell function were correlated more strongly with cluster-
ing of the components under a condition with low insulin 
sensitivity. Therefore, it may be suggested that in subjects 
with metabolic syndrome, vascular reactivity is impaired 
by multiple cardiovascular risk factors exclusively under 
the condition of insulin insensitivity and also that defin-
ing metabolic syndrome can effectively predict impair-
ment of vascular reactivity.
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